Jan 2022: Pembrolizumab (Keytruda, Merck) ay u ansixisay Maamulka Cuntada iyo Dawooyinka ee daawaynta adjuvant ee bukaanada qaba kansarka unugyada kelyaha (RCC) kuwaas oo ku jira dhexdhexaad-sare ama khatarta sare ee soo noqoshada ka dib nephrectomy, ama ka dib nephrectomy iyo dib-u-soo-saarka nabarrada metastatic.
Waxtarka ayaa lagu qiimeeyay bukaanada 994 ee leh dhexdhexaad-sare ama khatarta sare ee soo noqoshada RCC, ama M1 ma jirto caddayn jirro, gudaha KEYNOTE-564 (NCT03142334), xarun badan, randomized (1: 1), laba-indhoole, placebo-control. maxkamadayn. Bukaan-socodka waxaa la siiyay pembrolizumab 200 mg xididka 3 toddobaad kasta ama placebo ilaa hal sano, ama ilaa inta cudurku soo noqnoqonayo ama sunta aan loo dulqaadan karin, hadba kii soo horeeyay.
Badbaadinta cudur-la'aanta (DFS), oo lagu qeexay muddada u dhaxaysa soo noqoshada, metastasis, ama dhimashada, ayaa ahayd qiyaasta natiijada waxtarka aasaasiga ah. Guud ahaan badbaadada waxay ahayd cabbir kale oo natiijada (OS). Falanqaynta ku-meel-gaadhka ah ee la cayimay ayaa muujisay horumar la taaban karo oo ku yimid DFS, iyada oo 109 (22%) ay ka dhaceen cududda pembrolizumab iyo 151 (30%) dhacdooyinka cududda placebo (HR 0.68; 95 boqolkiiba CI: 0.53, 0.87; p=0.0010) . Labada dhinacba, waxaa la gaaray dhexdhexaadinta DFS. Xogta OS-da ma dhammays tirnayn markii la baarayey DFS, iyadoo 5% dadku ay dhinteen.
Xanuunka murqaha, daalka, finan, shuban, cuncun, iyo hypothyroidism ayaa ah saamaynta xun ee ugu badan ee tijaabadan (boqolkiiba 20).
Pembrolizumab waxaa la siiyaa qiyaaso 200 mg ah saddexdii usbuucba mar ama 400 mg lixdii usbuucba mar ilaa xanuunku soo noqdo, sun aan loo dulqaadan karin, ama ilaa 12 bilood.
Click here for full prescribing information for Keytruda.
